Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trialResearch in context
Summary: Background: The endothelium is supposedly activated and damaged in COVID-19 because of endothelin-1 over-secretion. This study evaluates the effect of bosentan as an endothelin receptor blocker on the progression of disease in high-risk outpatients with COVID-19 infection. Methods: From 15...
Main Authors: | Shaahin Shahbazi, Zahra Vahdat Shariatpanahi, Erfan Shahbazi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-08-01
|
Series: | EClinicalMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537023002948 |
Similar Items
-
Refeeding Syndrome and Its Related Factors in Critically Ill Coronavirus Disease 2019 Patients: A Prospective Cohort Study
by: Zahra Vahdat Shariatpanahi, et al.
Published: (2022-04-01) -
Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study
by: Lei Wang, et al.
Published: (2023-05-01) -
Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India
by: Aravind P. Gandhi, et al.
Published: (2023-03-01) -
Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study
by: Ke-Hsin Ting, et al.
Published: (2022-03-01) -
Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review
by: Angela Napolitano, et al.
Published: (2023-10-01)